Liver Failure - Pipeline Review, H1 2013 -





Published February 2013 Pages: 56 

 

Summary


Global Markets Direct’s, 'Liver Failure - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Failure. Liver Failure - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Liver Failure.
- A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Failure pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Failure Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Liver Failure 8
Liver Failure Therapeutics under Development by Companies 10
Liver Failure Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Liver Failure Therapeutics – Products under Development by Companies 16
Liver Failure Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Liver Failure Therapeutics Development 18
Silence Therapeutics plc. 18
EpiCept Corporation 19
Biotecnol SA 20
CREABILIS Therapeutics S.r.l. 21
Ventria Bioscience 22
Conatus Pharmaceuticals Inc. 23
FCB-Pharmicell Co.,Ltd. 24
Liver Failure – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Cardiotrophin-1 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CT-637 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
emricasan - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Adult Human Mesenchymal Stem Cells - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Allogeneic Bone Marrow Mesenchymal Stem Cells - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ALF-5755 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
F-573 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drug For Liver Diseases - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Picroliv - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TAT-ARC - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
optibumin Biosimilar - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Liver Failure Therapeutics – Drug Profile Updates 46
Liver Failure Therapeutics – Discontinued Products 48
Liver Failure Therapeutics - Dormant Products 49
Liver Failure – Product Development Milestones 50
Featured News & Press Releases 50
Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury 50
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 51
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 51
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 52
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 52
May 15, 2009: Cardiotrophin-1 Showed To Improve Ssurvival In A Rabbit Model Of Fulminant Hepatic Failure (FHF) Of Viral Origin 53
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI’s Key Therapeutic Product for Liver Disease 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56



List of Tables

Number of Products Under Development for Liver Failure, H1 2013 8
Products under Development for Liver Failure – Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
Silence Therapeutics plc., H1 2013 18
EpiCept Corporation, H1 2013 19
Biotecnol SA, H1 2013 20
CREABILIS Therapeutics S.r.l., H1 2013 21
Ventria Bioscience, H1 2013 22
Conatus Pharmaceuticals Inc., H1 2013 23
FCB-Pharmicell Co.,Ltd., H1 2013 24
Assessment by Monotherapy Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Liver Failure Therapeutics – Drug Profile Updates 46
Liver Failure Therapeutics – Discontinued Products 48
Liver Failure Therapeutics – Dormant Products 49



List of Figures

Number of Products under Development for Liver Failure, H1 2013 8
Products under Development for Liver Failure – Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Discovery and Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28

Assessment by Stage and Molecule Type, H1 2013 29